Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM-201 in Pediatric Growth Hormone Deficiency (OraGrowtH212)
NCT04806854Phase 2Active, not recruiting
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jul 2021
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibutamoren in growth hormone deficiency (GHD) (2 arms), sponsored by Lumos Pharma, Inc. Primary endpoints: Evaluation of Augmented Growth Hormone (GH) Pulsatility at Month 6 and Pharmacokinetics of LUM-201 and M8 at Month 6. Started Jul 2021; status: active, not recruiting.
02
Drugs
ibutamoren
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT04806854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04806854.